A Phase 2 interventional study of Pralatrexate and Erlotinib in Non-small Cell Lung Cancer, sponsored by Spectrum Pharmaceuticals, Inc. Completed at 47 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-05.
Sponsored by Spectrum Pharmaceuticals, Inc (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 519 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.
Among the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 624th largest by enrollment of the 2,995 interventional ones that give a count, is one of 114 that started in 2008, is one of 1,078 in phase 2, and was the 759th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →519 of the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
Indiana University · Sites in United States
Ages 18+
Exelixis · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,368 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1,411 · Phase 2 1,591 · Phase 3 382 · Phase 4 13
First in 1990; this study’s year is marked. 114 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 201 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 56 across the 2,995 interventional studies, 100 across the 246 observational. Of the 2,297 that completed or were terminated, 1,053 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
1,736 of 3,368 have an industry lead sponsor. The 10 most frequent:
This study is registered under Spectrum Pharmaceuticals, Inc, one of the names counted as Zydus Lifesciences Limited. Under that name alone:
Spectrum Pharmaceuticals, Inc is the lead sponsor of 60 studies on the registry; 1 is open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 12 (67%) have results posted.
Zydus Lifesciences Limited has 5 studies filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
272 of the studies in Carcinoma, Non-Small-Cell Lung with a site in United States that are under way reach primary completion within a year, 25 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05987956Phase 3Medicine Invention Design, IncPharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms | 2026-11-18 |
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT03637816Phase 3M.D. Anderson Cancer CenterAnamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer | 2026-12-31 |
| NCT05221840Phase 3AstraZenecaA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | 2027-01-08 |
Add all 272 to your calendar (.ics) → With an account.
Among the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to determine the effectiveness (ability to provide beneficial treatment of the disease) and safety of pralatrexate compared to erlotinib when given to non-small cell lung cancer (NSCLC) patients who are current or former cigarette smokers and who have received at least 1 prior treatment with a platinum drug (cisplatin or carboplatin)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).
Drug: Pralatrexate · Dietary Supplement: Vitamin B12 · Dietary Supplement: Folic Acid
150 mg orally in tablet form Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met.
Drug: Erlotinib · Dietary Supplement: Vitamin B12 · Dietary Supplement: Folic Acid
Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride). Initial dose: 230 mg/m2, increased to 270 mg/m2 if patient does not have specific adverse events (AEs) as per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/m2 decrements to 190 mg/m2 per the protocol defined dose modifications. Protocol amended dose: 190 mg/m2, then 230 mg/m2 if patient does not have specific AEs per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/2 decrements to 150 mg/m2 per the protocol defined dose modifications. Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met.
Also known as: FOLOTYN, PDX, (RS)-10-propargyl-10-deazaaminopterin
150 mg orally in tablet form Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met.
Also known as: Tarceva®, Erlotinib hydrochloride
1 mg intramuscular injection Administered within 10 weeks of randomization, every 8-10 weeks throughout the study and for at least 30 days after last dose of study treatment.
Also known as: Cyanocobalamin
1-1.25 mg orally Administered daily for at least 7 days prior to randomization, throughout the study and for at least 30 days after last dose of study treatment.
Also known as: Vitamin B9, Folate, Folacin
Overall Survival (OS) of Patients Receiving Pralatrexate vs. Erlotinib
OS was defined as the length of time from randomization until death due to any cause. Patients who were alive at the time of the data cut-off date were censored at the last contact date.
Time frame: Assessed from date of randomization no less frequently than every 16 weeks for up to 2 years after randomization.
Response Rate (RR) to Treatment of Patients Receiving Pralatrexate vs. Erlotinib
Number of patients whose tumors responded to Pralatrexate or Erlotinib, using the Response Criteria in Solid Tumors (RECIST).
Time frame: Assessed every 8 weeks for the first 24 weeks, then every 16 weeks for up to 2 years or until PD or start of subsequent treatment.
Progression-free Survival (PFS) of Patients Receiving Pralatrexate vs. Erlotinib
PFS was calculated as the number of days from randomization to the date of radiological evidence of PD or death due to any cause.
Time frame: Assessed every 8 weeks for the first 24 weeks, then every 16 weeks for up to 2 years or until PD or start of subsequent treatment.
Adverse Events of Patients Receiving Pralatrexate vs. Erlotinib
Time frame: Assessed every 2 weeks while on treatment through safety follow-up visit (35 +/-5 days post-last dose) or early termination visit (at time of withdrawal).
Patients were enrolled between January 2008 and June 2009 across 43 study sites in 6 countries.
| Milestone | Pralatrexate | Erlotinib |
|---|---|---|
| Started | 100 | 101 |
| Completed | 97 | 101 |
| Not completed | 3 | 0 |
| Withdrew: Randomized but not treated | 3 | 0 |
| Milestone | Pralatrexate | Erlotinib |
|---|---|---|
| Started | 97 | 101 |
| Completed | 97 | 98 |
| Not completed | 0 | 3 |
| Withdrew: Treatment ongoing at time of data cutoff | 0 | 3 |
OS was defined as the length of time from randomization until death due to any cause. Patients who were alive at the time of the data cut-off date were censored at the last contact date.
| Months Survival | Pralatrexate | Erlotinib |
|---|---|---|
| Overall Survival (OS) of Patients Receiving Pralatrexate vs. Erlotinib | 6.7 (5.3 to 9.0) | 7.0 (3.9 to 7.9) |
Number of patients whose tumors responded to Pralatrexate or Erlotinib, using the Response Criteria in Solid Tumors (RECIST).
| Participants | Pralatrexate | Erlotinib |
|---|---|---|
| Complete + Partial Response | 2 | 7 |
| Complete Response (CR) | 0 | 1 |
| Partial Response (PR) | 2 | 6 |
| Stable Disease (SD) | 33 | 35 |
| Progressive Disease (PD) | 29 | 36 |
| Disease Control (CR+PR+SD) | 35 | 42 |
| Unable to Evaluate | 2 | 0 |
| Missing (off or no treatment, not confirmed) | 31 | 20 |
PFS was calculated as the number of days from randomization to the date of radiological evidence of PD or death due to any cause.
| months | Pralatrexate | Erlotinib |
|---|---|---|
| Progression-free Survival (PFS) of Patients Receiving Pralatrexate vs. Erlotinib | 3.4 (2.1 to 4.7) | 2.8 (2.1 to 3.7) |
| Treated Participants | Pralatrexate | Erlotinib |
|---|---|---|
| At least one AE | 75 | 77 |
| Grade 3 AEs | 25 | 18 |
| Grade 4 AEs | 5 | 0 |
| At least one SAE | 14 | 2 |
Collected over Assessed every 2 weeks while on treatment through safety follow-up visit (35 +/-5 days post-last dose) or early termination visit (at time of withdrawal).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pralatrexate | — | 31/97 (32%) | 91/97 (93.8%) |
| Erlotinib | — | 32/101 (31.7%) | 94/101 (93.1%) |
| Event | Pralatrexate | Erlotinib |
|---|---|---|
| stomatitisGastrointestinal disorders | 9/97 | 0/101 |
| dyspnoeaRespiratory, thoracic and mediastinal disorders | 5/97 | 4/101 |
| respiratory failureRespiratory, thoracic and mediastinal disorders | 5/97 | 1/101 |
| thrombocytopeniaBlood and lymphatic system disorders | 4/97 | 0/101 |
| pyrexiaGeneral disorders | 2/97 | 4/101 |
| dehydrationMetabolism and nutrition disorders | 1/97 | 4/101 |
| sepsisInfections and infestations | 3/97 | 3/101 |
| leukopeniaBlood and lymphatic system disorders | 3/97 | 0/101 |
| abdominal painGastrointestinal disorders | 0/97 | 3/101 |
| pneumoniaInfections and infestations | 2/97 | 3/101 |
| Event | Pralatrexate | Erlotinib |
|---|---|---|
| stomatitisGastrointestinal disorders | 62/97 | 4/101 |
| diarrhoeaGastrointestinal disorders | 15/97 | 32/101 |
| dermatitis acneiformSkin and subcutaneous tissue disorders | 4/97 | 28/101 |
| fatigueGeneral disorders | 25/97 | 16/101 |
| dyspnoeaRespiratory, thoracic and mediastinal disorders | 12/97 | 22/101 |
| rash maculo-papularSkin and subcutaneous tissue disorders | 4/97 | 21/101 |
| anaemiaBlood and lymphatic system disorders | 20/97 | 12/101 |
| anorexiaMetabolism and nutrition disorders | 16/97 | 19/101 |
| nauseaGastrointestinal disorders | 12/97 | 17/101 |
| coughRespiratory, thoracic and mediastinal disorders | 11/97 | 17/101 |
| Age, Customized(participants) | Pralatrexate | Erlotinib | Total |
|---|---|---|---|
| Between 18 and 65 years | 58 | 60 | 118 |
| >=65 years | 42 | 41 | 83 |
| Age, Continuous(years) | Pralatrexate | Erlotinib | Total |
|---|---|---|---|
| Median | 63.0 ± 9.0 | 62.0 ± 9.1 | 63.0 ± 9.0 |
| Sex: Female, Male(Participants) | Pralatrexate | Erlotinib | Total |
|---|---|---|---|
| Female | 31 | 33 | 64 |
| Male | 69 | 68 | 137 |
| Region of Enrollment(participants) | Pralatrexate | Erlotinib | Total |
|---|---|---|---|
| United States | 31 | 37 | 68 |
| Czech Republic | 17 | 20 | 37 |
| Hungary | 17 | 15 | 32 |
| India | 11 | 12 | 23 |
| Brazil | 13 | 9 | 22 |
| Argentina | 11 | 8 | 19 |
The record gives a start of Jan 2008, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pralatrexate
Carcinoma, Non-Small-Cell Lung →
Spectrum Pharmaceuticals, Inc →